Authors:
Kiran Pulidindi, Kunal Ahuja
Download free PDF
Omega-3 Fatty Acids Market Size & Share 2026-2035
Report ID: GMI15126
|
Published Date: September 2026
|
Report Format: PDF/Excel/Dashboard/Platform
Download Free PDF
Explore Our Licensing Options:
Immediate Delivery Available
Download Free PDF
Omega-3 Fatty Acids Market
Get a free sample of this report
What are you hoping to find?
Your PDF is on its way. Tell us little about your research goal, and we'll help you find the most relevant market insights.
Omega-3 Fatty Acids Market Size
The global omega-3 fatty acids market was valued at USD 3.5 billion in 2025. It is projected to grow from USD 3.7 billion in 2026 to USD 5.2 billion by 2035, representing 4.1% CAGR from 2026 to 2035, according to latest report published by Global Market Insights Inc. [1]U.S. Food and Drug Administration (FDA), Qualified Health Claims: Letter of Enforcement Discretion for EPA and DHA Omega-3 Fatty Acids, fda.gov
Omega-3 Fatty Acids Market Key Takeaways
Market Leader: DSM-Firmenich led with over 12.1% market share in 2025.
Leading Players: Top 5 players in this market include DSM-Firmenich, BASF SE, Croda International, Aker BioMarine, Archer Daniels Midland, which collectively held a market share of 55% in 2025.
The market covers marine oils, microalgal oils, plant-based alpha-linolenic acid (ALA), prescription-grade pharmaceuticals, and high-concentration ethyl ester and triglyceride omega-3 ingredients used across dietary supplements, functional foods, infant nutrition, pharmaceuticals, and animal nutrition. It excludes retail consumer-packaged goods. The market grew from USD 2.540 billion in 2022 to USD 3.480 billion in 2025, recording a historical CAGR of ~10.9% driven by post-pandemic health awareness and investments in molecular distillation, enzymolysis, and purification infrastructure. [2]American Heart Association / Circulation, Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia (REDUCE-IT), ahajournals.org
Cardiovascular and metabolic health management remains a primary demand anchor. Clinical trials (such as REDUCE-IT) evaluating purified icosapent ethyl have demonstrated substantial reductions in ischemic cardiovascular events among high-risk, statin-treated patients, reinforcing demand for pharmaceutical-grade EPA concentrates [3]European Food Safety Authority (EFSA), Scientific Opinion on the Substantiation of Health Claims Related to EPA and DHA, efsa.europa.eu. Concurrently, regulatory authorities, including the U.S. FDA and European Food Safety Authority (EFSA), recognize qualified health claims linking EPA and DHA consumption with reduced risks of coronary heart disease and hypertension [4]Corbion N.V., Regulatory Approvals and Expansion of Algae-Derived Omega-3 DHA Solutions, corbion.com.
Supply chain dynamics are reshaping feedstock strategies. While wild marine fisheries remain the volume foundation, catch quota volatility, ocean-warming events, and aquaculture demand create supply variations. In response, commercial fermentation platforms producing microalgae-derived EPA and DHA provide scalable, marine-independent alternatives tailored to vegan, infant formula, and clean-label markets [6]KD Pharma Group, Acquisition of MEG-3® Marine Lipids Business and Global Manufacturing Scale, kdpharma.com.
Key Drivers
Clinical validation of concentrated EPA and DHA
Substantial clinical trial data linking purified eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) to triglyceride lowering, reduced cardiovascular event risk, and cognitive development support premiumization. Authorized health claims encourage consumers and healthcare practitioners to favor high-potency, pharmaceutical-grade concentrates over standard 18:12 crude fish oils.
Rising global prevalence of cardiovascular and lifestyle diseases
Cardiovascular conditions represent a leading contributor to global mortality, driving demand for preventative nutrition and prescription therapeutics . Consumers increasingly utilize high-concentration omega-3 supplements to manage dyslipidemia, hypertension, and systemic inflammation.
Demand for sustainable, marine-independent algal sources
Environmental concerns surrounding overfishing and marine ecosystem conservation drive brand owners toward fermentation-derived microalgal oils. Algal platforms offer high-potency EPA/DHA without heavy metal contamination (such as mercury and PCBs), aligning with vegan preferences and infant formula safety standards.
Key Restraints
High purification, fractionation, and fermentation costs
Transforming crude lipid feedstocks into high-purity (>80%) ethyl ester or re-esterified triglyceride (rTG) concentrates requires multi-stage molecular distillation, supercritical fluid chromatography, and enzymolysis [7]GC Rieber VivoMega, High-Concentrate Omega-3 Production Expansion and Distillation Infrastructure, vivomega.com. Similarly, algal heterotrophic fermentation requires high capital and operational expenditures, restricting adoption in price-sensitive bulk food sectors.
Marine catch quota volatility and ecological limits
Marine-derived omega-3 depends on wild reduction fisheries (e.g., Peruvian anchoveta, menhaden), which are vulnerable to climatic disruptions (El Niño cycles) and regulatory biomass catch quotas. Supply tightness elevates crude oil costs and creates margin pressure for converters.
Sensory and oxidative stability challenges
Polyunsaturated fatty acids oxidize rapidly, generating volatile secondary oxidation by-products that produce unpleasant fishy odors and off-flavors. Fortifying functional foods and beverages requires advanced microencapsulation, deodorization, and antioxidant stabilization systems .
GMI Analyst View
The omega-3 market is transitioning from an undifferentiated commodity oil trade to a multi-tiered functional ingredient industry. While marine sources will maintain volume dominance through 2035, margin growth is concentrated in high-assay concentrates (rTG and ethyl esters), specialized EPA-only therapeutics, and fermentation-derived algal oils. Companies that integrate secure sustainable feedstocks with proprietary concentration technologies and clinical dossiers will capture the highest market realization.
Omega-3 Fatty Acids Market Segment Analysis
By Product Type
Marine-derived omega-3 generated USD 2.262 billion in 2025 (approximately 65% market share) and is projected to reach USD 3.409 billion by 2035 at a 3.5% CAGR . Anchovy, sardine, menhaden, tuna, and krill oils remain foundational to dietary supplements, clinical nutrition, and aquafeed due to cost efficiency and established processing scale [8]Amarin Corporation, Commercialization and Licensing Agreements for Icosapent Ethyl Therapeutics, amarincorp.com.
Algal-derived omega-3 accounted for USD 0.313 billion in 2025 and represents the fastest-growing product category (3.9% CAGR), forecast to reach USD 0.472 billion by 2035 . Grown under controlled closed-loop fermentation, algal oils bypass marine supply volatility, provide sensory-neutral profiles, and secure essential regulatory approvals in major international infant nutrition and functional food markets. Plant-based ALA (flaxseed, chia) and synthetic concentrates account for the remaining product share.
By Application
General wellness and dietary supplements represents the largest application segment, valued at USD 1.044 billion in 2025 and projected to reach USD 1.464 billion by 2034 . Demand is driven by softgels, liquid emulsions, and gummies targeting joint, eye, prenatal, and general metabolic health. Cardiovascular health represents the second-largest and most clinically validated segment (USD 835 million in 2025, reaching USD 1.171 billion by 2034), supported by prescription therapeutics and high-dose EPA supplements . Infant nutrition, maternal health, and clinical enteral nutrition represent high-value segments with strict purity thresholds.
By End-Use Industry
Nutraceuticals and dietary supplements leads end-use demand at USD 1.531 billion in 2025 (44% revenue share), forecast to reach USD 2.140 billion by 2034 . The pharmaceutical sector represents a fast-growing high-margin segment, utilizing pure (>96%) EPA ethyl esters for hypertriglyceridemia therapeutics. Food and beverage fortification incorporates microencapsulated powders into dairy, plant-based milks, and bakery products, while animal feed and aquaculture utilize marine and algal lipids to optimize EPA/DHA retention in farmed salmon and livestock.
GMI Analyst View
Application value is diverging based on technical specifications. While bulk dietary supplements require cost-competitive marine oils, infant formula and functional beverages command premiums for algal DHA and microencapsulated powders that guarantee zero fishy off-notes. In pharmaceuticals, single-molecule purity and patent protection insulate producers from general commodity cycles.
Omega-3 Fatty Acids Market Regional Analysis
North America
North America was the largest regional market at USD 1.044 billion in 2025 and is projected to reach USD 1.573 billion by 2035 at a 2.7% CAGR . The United States accounted for USD 0.928 billion in 2025. Regional growth is supported by high dietary supplement penetration, established prescription reimbursement pathways for concentrated EPA therapeutics, and FDA-qualified health claim frameworks.
Europe
Europe reached USD 0.939 billion in 2025 and is projected to reach USD 1.415 billion by 2035 (2.6% CAGR) . Demand across Germany, the UK, France, and the Nordics is driven by strict EFSA-backed health claims, advanced lipid distillation capacity in Norway and Germany, and consumer preference for certified sustainable (MSC/Friend of the Sea) and algal omega-3 products.
Asia Pacific
Asia Pacific is the fastest-growing regional market, valued at USD 0.974 billion in 2025 and projected to expand at a 5.3% CAGR to USD 1.468 billion by 2035 . China and India drive market expansion through rising consumer disposable incomes, premium infant formula fortification, expanding domestic supplement manufacturing, and aquaculture operations requiring sustainable lipid alternatives [5]Nature Food, Forage Fish Supply Dynamics and Alternative Lipid Ingredients in Global Aquaculture, nature.com.
Latin America & MEA
Latin America was valued at USD 0.348 billion in 2025 and is forecast to reach USD 0.524 billion by 2035 (3.7% CAGR), anchored by fish oil extraction in Peru and Chile and expanding consumer markets in Brazil . Middle East & Africa generated USD 0.174 billion in 2025 (USD 0.262 billion by 2035; 3.7% CAGR), where demand centers on halal-certified, shelf-stable supplement formats across Saudi Arabia and the UAE.
GMI Analyst View
Asia Pacific represents the primary growth engine for volume and algal adoption, whereas North America and Europe remain the highest-value markets for clinical concentrates and pharmaceutical applications. Regional success requires aligning product offerings with local health claims, novel food clearances, and supply chain logistics.
Omega-3 Fatty Acids Market Share & Competitive Landscape
The global omega-3 fatty acids market features a consolidated tier of integrated processors alongside specialized pharmaceutical and biotechnology innovators. The top five suppliers accounted for approximately 55% of global market revenue in 2025:
Recent Industry Developments
Need a specific section of this report?
Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.
Frequently Asked Question(FAQ) :
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Industry journals, trade publications, and specialized media.
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 20+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →